Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Saruparib - AstraZeneca

Next Previous
Drug Profile

Saruparib - AstraZeneca

Alternative Names: AZD-5305

Latest Information Update: 13 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Amides; Antineoplastics; Naphthyridines; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Prostate cancer
  • Phase II Solid tumours

Most Recent Events

  • 06 Aug 2025 Phase-III clinical trials in Prostate cancer (Late-stage disease, First-line therapy, Adjuvant therapy) in USA (PO) (NCT06952803)
  • 11 Jul 2025 AstraZeneca plans a phase I/II trial for Ovarian cancer (Recurrent, Late stage disease, Neoadjuvant therapy, Combination therapy, Monotherapy, First line therapy) in USA, South Korea, Italy, Spain (PO) (NCT07060365)
  • 01 May 2025 AstraZeneca plans a phase III trial for Prostate cancer (Late-stage disease, Newly-diagnosed, Adjuvant therapy) in Austria, Belgium, Brazil, Canada, Finland, France, Germany, Italy, Peru, Poland, Sweden, Thailand, United States (PO) (NCT06952803)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top